1. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511, 421–427;

2. Kuzman MR, Medved V, Terzic J, Krainc D. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia. Journal of psychiatric research 2009; 43(13):1073–7.

3. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B, et al. Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. Journal of psychiatric research 2013; 47(4):425–37.

4. de Jong S, Boks MPM, Fuller TF, Strengman E, Janson E, de Kovel CGF, et al. A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. PloS one 2012; 7(6):e39498.

5. Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, et al. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. International Journal of Neuropsychopharmacology 2013; 16(7):1483–503.

6. Wu JQ, Green MJ, Gardiner EJ, Tooney PA, Scott RJ, Carr VJ, Cairns MJ. Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: A transcriptome analysis. Brain, Behavior, and Immunity 2016; 53:194–206.

7. Lee J, Goh LK, Chen G, Verma S, Tan CH, Lee TS. Analysis of bloodbased gene expression signature in first-episode psychosis. Psychiatry research 2012; 200(1):52–4.

8. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The lancet Psychiatry 2015; 2(3):233–8.

9. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. The British journal of psychiatry: the journal of mental science 2009; 195(6):488–91.

10. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological psychiatry 2012; 72(10):811–6.

11. Bebbington P, Nayani T. The psychosis screening questionnaire. International Journal of Methods in Psychiatric Research 1996; 5(1):11–9.

12. Team RC. R: A language and environment for statistical computing. 2013. URL: http://www.r-project.org/.

13. Xie Y, Wang X, Story M. Statistical methods of background correction for Illumina BeadArray data. Bioinformatics 2009; 25(6):751–7.

14. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547–8.

15. Oldham MC, Langfelder P, Horvath S. Network methods for describing sample relationships in genomic datasets: application to Huntington’s disease. BMC Systems Biology 2012; 6(63).

16. Rousseeuw P, Croux C, Todorov V, Ruckstuhl A, Salibian-Barrera M, Verbeke T, et al. robustbase: Basic Robust Statistics. URL: http://CRAN.R-project.org/package=robustbase

17. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nature reviews Genetics

18. Gaujoux R, Seoighe C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics (Oxford, England) 2013; 29(17):2211–2.

19. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004; Vol. 3(No. 1): Article 3.

20. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics 2008; 9:559.

21. Miller JA, Horvath S, Geschwind DH. Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proceedings of the National Academy of Sciences 2010; 107(28):12698–703.

22. Bayes A, van de Lagemaat LN, Collins MO, Croning MDR, Whittle IR, Choudhary JS, Grant SGN. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat

Neurosci 2011; 14(1):19–21.

23. Stefansson H, Ophoff Ra, Steinberg S, Andreassen Oa, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature 2009; 460(7256):744–7.

24. Broadbelt K, Ramprasaud A, Jones LB. Evidence of altered neurogranin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex. Schizophrenia Research 2015; 87(1):6–14.

25. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2002; 101(6):2285-93.

26. Beites CL, Campbell KA, Trimble WS. The septin Sept5/CDCrel-1 competes with α-SNAP for binding to the SNARE complex. Biochemical Journal 2005; 385(2):347–53.

27. Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim SY, et al. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. Journal of Neurochemistry

2005; 94(4):1040–53.

28. Dent J, Kato K, Peng XR, Martinez C, Cattaneo M, Poujol C, et al. A prototypic platelet septin and its participation in secretion. Proceedings of the National Academy of Sciences 2002; 99(5):3064–9.

29. Williams HJ, Owen MJ, O’Donovan MC. Is COMT a Susceptibility Gene for Schizophrenia? Schizophrenia Bulletin 2007; 33(3):635–41.

30. Bassett AS, Chow EWC, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R. The Schizophrenia Phenotype in 22q11 Deletion Syndrome. The American Journal of Psychiatry 2003; 160(9):1580–6.

31. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Archives of General Psychiatry 1999; 56(10):940–5.

32. Lazier K, Chow EWC, AbdelMalik P, Scutt LE, Weksberg R, Bassett AS. Low platelet count in a 22q11 deletion syndrome subtype of schizophrenia. Schizophrenia Research 2015; 50(3):177–80.

33. Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M, Bahn S. Increased alpha-defensins as a blood marker for schizophrenia susceptibility. Molecular & cellular proteomics: MCP 2008; 7(7):1204–13.

34. Iavarone F, Melis M, Platania G, Cabras T, Manconi B, Petruzzelli R, et al. Characterization of salivary proteins of schizophrenic and bipolar disorder patients by top-down proteomics. Journal of proteomics 2014; 103:15–22.

35. Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, Geschwind DH. Functional organization of the transcriptome in human brain. Nature Neuroscience 2008; 11(11):1271–82.

36. Lewis T, Wood S, Michaelis E, DuPont B, Leach R. Localization of a Gene for a Glutamate Binding Subunit of a NMDA Receptor (GRINA) to 8q24. Genomics 1996; 32(1):131–3.

37. Bonaglia MC, Giorda R, Tenconi R, Pessina M, Pramparo T, Borgatti R, Zuffardi O. A 2.3 Mb duplication of chromosome 8q24.3 associated with severe mental retardation and epilepsy detected by standard karyotype. European Journal of Human Genetics 2005; 13(5):586–91.

38. Goswami DB, Jernigan CS, Chandran A, Iyo AH, May WL, Austin MC, et al. Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013; 43:126–33.

39. Schubert KO, Focking M, Cotter DR. Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: Potential roles in GABAergic interneuron pathology. Schizophrenia Research 2015;

40. English JA, Pennington K, Dunn MJ, Cotter DR. The Neuroproteomics of Schizophrenia. Biological Psychiatry 2011; 69(2):163–72.

41. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. American Journal of Psychiatry 2011; 168(12):1303–10.

42. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460(7256):748–52.

43. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood. Journal of Alzheimer’s disease 2012; 30(3):685–710.

44. Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I. Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson’s disease brain is region dependent 2014;24(6):584–98.

45. Vogelzangs N, Beekman ATF, Van Reedt Dortland AKB, Schoevers RA, Giltay EJ, De Jonge P, Penninx BWJH. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users 2014; 39(7):1624–34.

46. Vijayakumar NT, Judy MV. Autism spectrum disorders: Integration of the genome, transcriptome and the environment. Journal of the Neurological Sciences 2016; 364:167–76.

47. Wang P, Bouwman FG, Mariman ECM. Generally detected proteins in comparative proteomics - A matter of cellular stress response? Proteomics 2009; 9(11):2955–66.